| Molecular Weight |
579.98 |
| Formula |
C26H21ClF3N3O5S |
| CAS No. |
1049704-18-8 |
| SMILES |
O=C1C(NCC2=CC=C(Cl)C=C2)=CC3=NCCC4=CN(S(=O)(C5=CC=C(C)C=C5)=O)C1=C34.FC(F)(C(O)=O)F |
| Shipping |
Room temperature in continental US; may vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| In Vitro |
MA242 (0.05-5 μM; 72 hours) significantly inhibits pancreatic cancer cell growth, with IC50s ranging from 0.1 to 0.4 μM, regardless of the p53 status of the cells. However, MA242 shows minimal effects on the growth of normal HPDE cells (IC50=5.81 μM), indicating that MA242 has selective effects against cancer cells.
MA242 (0.1-0.5 μM; 24 hours) significantly decreases the MDM2 and NFAT1 protein levels at a low concentration in all three cell lines.
MA242 decreases cell proliferation and induces apoptosis in pancreatic cancer cell lines regardless of p53 status.
MA242 alone or in combination with Gemcitabine inhibits pancreatic tumor growth and metastasis without any host toxicity.
MA242 exerts cytotoxicity against hepatocellular carcinoma (HCC) cells by inhibiting the NFAT1-MDM2 pathway in vitro, independent of p53. MA242 shows selective cytotoxicity against HCC cells, with IC50 values ranging from 0.1-0.31 μM. |
| In Vivo |
MA242 (IP; 2.5, 5, 10 mg/kg) suppresses orthotopic pancreatic tumor growth in vivo, independent of p53.
There were no significant differences in the average body weights between the vehicle- and MA242-treated mice in either of the models, did not have significant host toxicity at these effective doses. |
